HistoRx Inc., a cancer therapy diagnostics firm based in New Haven, won a $1.5 million loan from Connecticut’s quasi-public life sciences initiative.
HistoRx is developing what it calls AQUA, technology designed to assess the potential effectiveness of cancer drugs and predict patients’ responses to the treatments. The system uses fluorescence-based image analysis and automated microscopy to measure protein molecules. Connecticut Innovations, the quasi-public equivalent of the Mass. Life Sciences Center, is loaning the company $1.5 million to build out laboratory space and buy equipment.
The company will use some of the infusion to establish a CLIA-certified testing lab for clinical trials, according to a press release. HistoRx was founded in 2005 to commercialize technology developed at Yale University. The company has more than 40 issued and pending patents.
